Fewer than 4 Weeks Left to Participate in ARNA Genomics ICO

Share Article

What If We Never Had to Treat Stage 3 Cancer Again?

ARNA Genomics logo
Can you imagine a world in which we never have to treat stage 3 breast cancer?

ARNA Genomics, an innovative Precision Medicine and Blockchain technology company, today announced that it has passed the Soft Cap threshold by raising over $1M amid an Initial Coin Offering (ICO) from over 200 investors spanning nations such as the United States, Canada, Germany, France, China, Japan, Australia, among others.

ARNA Genomics, currently based in Russia, aims to use the funding, still ongoing through February 10, 2018, toward moving its breast cancer testing and diagnostic services to the US.

Leveraging Blockchain technology in its proprietary suite of Liquid Biopsy tests, ARNA has set out to bring the benefits of Precision Medicine to everyone with its affordable breast cancer test which helps diagnose the disease earlier, better, and cheaper -- while accelerating trust in collaborative biomedical research -- leading to more positive prognosis for patients and reducing disease burden for all.

Started by 5 lifelong friends with a track record of science, innovation, and entrepreneurship, ARNA’s founding team is excited to prepare for the rigors of FDA trials and approvals. The team includes:

  • Dr. Anatoly Melnikov, Chief Scientist and inventor of ARNA’s proprietary diagnostic technology with 40 years of experience in Oncology, molecular biology, and genetics R&D
  • Egor Melnikov, CEO, an economist and serial entrepreneur
  • George Nikitin, COO, a physicist and inventor with over 10 years of management and consulting experience

For more on the management team, click here.

ARNA is proud to be advised by a global team of subject-matter experts including Dr. Ron Ribitzky, MD, CEO of R&D Ribitzky; Dr. Alex Kosik, MD, medical device expert and angel investor; Dr. Mehdi Benchoufi, MD, Chef de Clinique, Hopital Hotel Dieu; Dr. Dmitry Kulish, PhD, Professor, Skolkovo Institute of Science and Technology; Dr. Linda Pellicore, PhD, Sr. Pharmacologist, FDA (Ret.); Dr. Wesley Hymer, PhD, Emeritus Professor of Biochemistry, Penn State University; among others. For more on the Advisory Board, click here.

ICO Deadline Approaching

Investors and the public at large who are interested in learning more about the ICO, and the potential to participate in this round, should note the deadline for issuing ARNA Tokens ends on February 10, 2018. https://token.arnagenomics.com

About ARNA Genomics

Based in Moscow, Russia, ARNA Genomics is an innovative Precision Medicine and Blockchain technology company specializing in the development of blood tests for early diagnosis of cancer and monitoring the efficacy of cancer treatment tied to ARNA Panacea, a Blockchain Proof-Of-Research protocol designed to accelerate and lower the cost of consumer access to trusted, collaborative Precision Medicine worldwide.

Related Links
https://token.arnagenomics.com

Contact Information:
Ron Ribitzky MD
Advisor, ARNA Genomics
Founder & CEO, R&D Ribitzky
ron(at)rdribitzky(dot)com
Office: +1 [617] 244 - 5063

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dr. Ron Ribitzky, MD
R&D Ribitzky
+1 (617) 244-5063
Email >
@RonRibitzkyMD
since: 04/2011
Follow >
R&D Ribitzky

Visit website